Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Sleep Researcher Receives Award for Work in Wakefulness and Narcolepsy

12 September 2026 · By · Wire by Fusion42

Published

12 September 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at respiratory-therapy.com →

◆ Verified

Fusion42 · 12 September 2026 · Fusion42 review

Masashi Yanagisawa won the 2026 Albert Lasker Basic Medical Research Award for discovering orexin, essential for wakefulness, leading to new sleep disorder treatments including orexin-activating therapy oveporexton approved by the FDA for narcolepsy Type 1.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You can now build on the proven role of orexin in wakefulness to develop therapies targeting narcolepsy and insomnia, as FDA approval of oveporexton signals rising market acceptance and regulatory support.

◆ Coverage

1 source · 12 Sep 2026

◆ Related on Wire

◆ Topics

Healthsleep-disordersorexinnarcolepsyFDA-approvalclinical-therapies